Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050167 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 603
- Enrollment target
NCT00050167: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00050167 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 603 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050167, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 603 participants
- Enrollment target
Study Summary
Primary Objectives: * Determine the impact of each regimen on the disease free and overall survival of patients with operable breast cancer. * Determine the ability of docetaxel/capecitabine to downstage primary breast cancer when administered in the neoadjuvant setting when compared with weekly paclitaxel. * Determine the ability of each regimen to enhance breast conservation therapy when administered in the neoadjuvant setting. (See protocol text for additional objectives and details).
Interventions
- DRUG Docetaxel
- DRUG Capecitabine
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 603 participants |
| Start Date | 2002-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050167
The ClinicalTrials.gov registry entry for NCT00050167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 603 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00050167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050167 about?
NCT00050167 is a clinical study titled "Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer". Primary Objectives: * Determine the impact of each regimen on the disease free and overall survival of patients with operable breast cancer. * Determine the ability of docetaxel/capecitabine to downstage primary breast cancer when administered in the neoadjuvant setting when compared with weekly pa...
What is the current status of trial NCT00050167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 603 participants. The study started on 2002-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00050167?
The interventions under investigation include: Docetaxel (DRUG), Capecitabine (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00050167?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.